Explore the Agenda
7:30 am Check In & Morning Coffee
8:20 am Chair’s Opening Remarks
Driving Precision Medicine in the General Population Through Improved Diagnostics & Strategic Partnerships
8:30 am Equitable Biomarker Testing: Findings from the Delivering Accurate Real-Time Biomarker Testing (DART) Research
- Understanding barriers to biomarker testing from the Delivering Accurate Real-time biomarker Testing (DART) research
- Implications for patients and the workforce
- Does genomics widen health inequalities
8:50 am Session Reserved for Myriad Genetics
Presentation details to be announced
9:20 am Accelerating the Future of Oncology Through ctDNA-Guided Clinical Development With Natera
Presentation details to be announced
9:50 am Improving Rare Disease Diagnostics With Multiomics
- Short-read whole genome sequencing has revolutionised the diagnosis of rare diseases in clinical services, but nonetheless still only 25-30% of patients achieve a diagnosis
- New ‘omics approaches including long-read sequencing and epigenetic profiling, transcriptomics, proteomics, and metabolomics offer the potential to increase this proportion, including in non-European ancestry patients
- Genomics England’s rare disease program pilot analyses suggest that using combinations of these approaches may lift the overall proportion of rare disease patients receiving a genetic diagnosis to over 40%, of great benefit to the families concerned
10:10 am Session Reserved for Personalis
Presentation details to be announced
10:40 am Precision Medicine at Scale: Innovation, Efficiency & Global Reach With Illumina
Presentation details to be announced
11:10 am Morning Break & Networking & Dedicated 1-to-1 Networking
TRACK A: Biomarker Discovery & Translation
TRACK B: Clinical & CDx Development
TRACK C: Rx-Dx Commercialisation & Adoption
TRACK A: Biomarker Discovery & Translation
Exploring Biomarker Strategies for Novel Conjugate Therapies to Refine Treatment Decisions
12:00 pm Biomarker-Driven Development of Multispecific ADCs: From Target Qualification to Patient Stratification
Chief Scientific Officer, Valink Therapeutics
- How biomarker-driven target qualification, internalisation kinetics, and payload sensitivity shape the success or failure of modern ADCs
- Practical approaches to stratifying patients in heterogeneous tumours
- Translational biomarkers that link target biology with payload exposure – enabling better dose selection, early efficacy signals, and rational design of multispecific ADCs
12:20 pm Establishing a Biomarker-Driven Approach to Guide Patient Selection for pre|CISION® Peptide-Drug Conjugates Using Tumour Targeting/Release & Payload Sensitivity Biomarkers
Translational Scientist, Avacta Therapeutics
- Avacta’s pre|CISION® peptide-drug conjugates comprise a peptide moiety bound to a cytotoxic payload by a linker that is specifically cleaved by FAP, a protease selectively overexpressed in the tumour microenvironment of many solid tumours
- AVA6000 (FAP-activated doxorobucin) is completing Phase 1b and has shown promising results, whilst AVA6103 (FAPactivated exatecan) is due to enter the clinic in Q1 2026
- A pan-cancer evaluation of FAP expression across multiple datasets supports the identification of tumour types most likely to benefit from FAP-activated pre|CISION® therapeutics
- Pan-cancer evaluation of DNA-damage response pathways enables identification of patient subsets most likely to benefit from payload-driven therapeutic activity
TRACK B: Clinical & CDx Development
TRACK C: Rx-Dx Commercialisation & Adoption
12:40 pm Lunch Break & Dedicated 1-to-1 Networking
TRACK A: Biomarker Discovery & Translation
TRACK B: Clinical & CDx Development
TRACK C: Rx-Dx Commercialisation & Adoption
TRACK A: Biomarker Discovery & Translation
Integrating High Sensitivity Biomarkers for More Accurate Prediction & Tailored Disease Management in Chronic & Neurological Indications
2:00 pm How to Develop a Translational Assay for Target Engagement to Support Preclinical Drug Development in Neurodegenerative Disorders
Director Translational Science, Bioassays & Biomarkers, AviadoBio
- Reviewing the concept of translation assay development
- Showcasing tools available
- Optimising design principles
2:20 pm Translating Neurological Biomarkers into Predictive & Prognostic Diagnostic Tools for Therapy Qualification
Co-Founder & Chief Scientific Officer, Monument Therapeutics
- How to define the unmet need for biomarkers in neurological diseases so that patient eligibility for novel therapies is better established and trial recruitment becomes more efficient?
- How to leverage diagnostic platforms such as mass spectrometry or high-sensitivity immunoassays so that biomarker measurements become more standardised and comparable across trials, enabling broader clinical adoption?
- What is the regulatory pathway in Europe for neurological biomarkers compared with oncology?
TRACK B: Clinical & CDx Development
TRACK C: Rx-Dx Commercialisation & Adoption
4:20 pm Afternoon Break & Dedicated 1-to-1 Networking
Optimising Translational Infrastructure for Faster Clinical Decisions & More Confident Early-Stage Rx-Dx Developments
3:40 pm Building Resilient Biomarker Infrastructure: From Pandemic Preparedness to Clinical Testing Excellence
- Accelerating biomarker delivery through integrated assay platforms – how Moderna’s UK Clinical Biomarker Laboratory is enabling rapid, compliant deployment of immunoassay, cytometry, and molecular methods for global clinical programs
- Embedding automation and AI in sample and data workflows – leveraging robotic biobanking, and digital traceability to enhance efficiency, reproducibility, and data integrity
- Pandemic preparedness and translational resilience – establishing high-containment and rapid-assay transfer capabilities to respond to emerging pathogens and future public-health challenges
4:00 pm Translational Plans for a Novel, First-in-Class Biologic to Treat Early-Stage Malignancies
- Highlighting how multiple tracks of biomarkers are needed to confirm target engagement
- Showcasing early readouts of PD activity to support dose selection is critical